Preconditioning EG7 tumor-bearing mice with a single low dose of doxorubicin or paclitaxel promoted ACT efficacy, with more activated and longer-sustained CD8+ T cells, probably due to MDSC inhibition via suppression of NF-κB and its associated immunosuppressive factors (Hsu et al., 2015). This evidence concerns the gene CD8A and neoplasm.